The story of Viagra and its originator, copyright, presents a complex picture for cautious investors. While the iconic drug initially fueled enormous earnings, its protection has ended, leading to generic options flooding the landscape . This reduction in pricing presents a substantial obstacle for copyright and any company considering a large stak